FLT3/ITD Allelic Ratio Test in UAE | 1000 AED | 2026 DHA Guidelines

تحليل طفرة FLT3/ITD (النمط الأليلي) في الإمارات | 1000 درهم | معتمد من هيئة الصحة بدبي

Executive Summary

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Fragment Analysis (PCR-based capillary electrophoresis).
Premium Logistics: Hospital-Grade Home Collection (8 AM – 11 PM) with ISO Certified Cold‑Chain Transport of bone marrow or peripheral blood.
Clinical Guidance: Complimentary Telephonic Post‑Test Interpretation with a DHA‑Licensed Consultant, available in English and Arabic.
Insurance: Direct Billing Verification for major UAE insurers via WhatsApp +971 54 548 8731.

الملخص التنفيذي

يقدم اختبار FLT3/ITD Allelic Ratio دقة تشخيصية فائقة بنسبة 99.9% وفقًا لمعايير الآيزو 9001:2015، مع خدمة سحب منزلي متميزة ونقل مبرّد، بالإضافة إلى استشارة طبية هاتفية بعد النتيجة. التحقق من التأمين متاح عبر واتساب على الرقم +971 54 548 8731.

Test Overview

The FLT3/ITD Allelic Ratio test quantifies internal tandem duplications in the FLT3 gene using high‑resolution fragment analysis, essential for risk stratification in acute myeloid leukemia (AML) and other hematologic malignancies. (يقيس اختبار FLT3/ITD Allelic Ratio نسبة التضاعفات الجينية في جين FLT3 لتصنيف خطورة ابيضاض الدم النقوي الحاد بدقة عالية.)

Turnaround time is 8–10 working days from receipt of a properly collected bone marrow or peripheral blood sample, supported by ISO‑certified logistics and DHA‑mandated quality control.

Feature	Our Test (FLT3/ITD Allelic Ratio)	Closest Alternative (NGS Panel)
Precision / Methodology	Fragment Analysis (PCR + Capillary Electrophoresis) – gold standard for ITD quantification	Next‑Generation Sequencing (NGS) – qualitative detection, less precise for allelic ratio
Speed (TAT)	8–10 working days	14–21 working days
Sample Requirements	Bone marrow or peripheral blood (transport immediately, cold-chain)	Often requires bone marrow; blood may be insufficient

Clinical Insight & Safety from Dr. Prabhakar Reddy (DHA: 61713011)

“As a DHA‑licensed consultant, I emphasise that the FLT3/ITD allelic ratio is a critical biomarker for AML prognosis and treatment selection; however, results must always be interpreted alongside full blood counts, bone marrow morphology, and clinical context. No single test replaces comprehensive oncologic evaluation, and I urge patients to discuss findings with their haematologist before making any treatment changes.”
— Dr. Prabhakar Reddy, DHA License 61713011

Medication Warning & Safety Precaution

Do not discontinue prescribed medication without consulting your doctor. This test does not replace therapeutic management. Haematological decisions should be made by a qualified specialist based on integrated results.

Exclusion Criteria & ER Red Flags

Active severe infection or sepsis – postpone collection until stabilised.
Platelet count <20 × 10⁹/L without physician clearance – risk of bleeding at puncture site.
Confirmed pregnancy (bone marrow aspiration only with explicit obstetric consent).
Current anticoagulant therapy that cannot be held – requires specialist approval.
Emergency warning: If you experience sudden high fever, uncontrolled bleeding, or acute confusion, contact your physician or call 998 immediately.

All home collections comply with Federal Decree‑Law No. 41 of 2024 (Art. 87), CDS Law 2026 (minor consent), and UAE PDPL data privacy standards.

Frequently Asked Questions

1. What does the FLT3/ITD Allelic Ratio test detect?

FLT3/ITD Allelic Ratio test detects internal tandem duplications in the FLT3 gene, impacting AML prognosis and guiding targeted therapy decisions. The analysis measures the proportion of mutated versus wild‑type alleles, providing a quantitative marker that helps haematologists estimate relapse risk and potential benefit from FLT3 inhibitors.

يكشف اختبار FLT3/ITD Allelic Ratio عن التضاعفات الجينية الداخلية في جين FLT3، مما يؤثر على تكهّن ابيضاض الدم النقوي الحاد ويوجه قرارات العلاج الموجه.

2. How is the sample collected and what are the requirements?

A DHA‑licensed phlebotomist collects bone marrow (by a qualified clinician) or peripheral blood using strict cold‑chain protocols; the sample must be transported to the lab immediately. Bone marrow aspiration requires a doctor’s prescription and is performed only in certified settings; for peripheral blood, 2–4 mL in EDTA tube is sufficient.

يتم جمع العينة من نخاع العظم بواسطة طبيب مرخص أو سحب الدم المحيطي بواسطة فني معتمد وفق بروتوكولات التبريد الصارمة، ويجب نقلها فوراً إلى المختبر.

3. Is a prescription mandatory and what about insurance coverage?

A valid doctor’s prescription is required for the FLT3/ITD Allelic Ratio; however, it is not applicable for pre‑surgical clearance, pregnancy cases, or travel health checks. Most UAE insurance plans cover medically indicated molecular diagnostics – send your policy details via WhatsApp to +971 54 548 8731 for instant eligibility verification and direct billing support.

يلزم وصفة طبية صالحة لإجراء هذا الاختبار، ولا ينطبق على حالات الجراحة أو الحمل أو السفر. تغطي معظم خطط التأمين الفحوصات الجزيئية الطبية – أرسل تفاصيل وثيقتك عبر واتساب للتحقق الفوري.

This service abides by Federal Decree‑Law No. 41 of 2024 (Art. 87 on clinical laboratory operations), CDS Law 2026 (consent for minors), and UAE Personal Data Protection Law. ISO 9001:2015 Certificate INT/EGQ/2509DA/3139. Facility License: 9834453. All clinical interpretations are performed by DHA‑licensed professionals.

دعم ثنائي اللغة متاح